The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat

The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat

Bibliographic Details
Main Authors: Jendle, J, Nauck, M, Matthews, D, Frid, A, Hermansen, K, During, M, Zdravkovic, M, Strauss, B, Garber, A
Format: Journal article
Published: 2008
Description
Summary:

Similar Items